Bullish on pharma sector: Sudip Bandyopadhyay

In a chat with ET Now, Sudip Bandyopadhyay, President, Destimoney Securities Pvt. Ltd., shares his views on Pharma space.


ET Now: It is a bit of a pharma today, there is Biocon which has done well, Shasun Pharma is an event based move up 20%, Orchid couple of others doing well too what is happening here particularly with Biocon?

Sudip Bandyopadhyay: Well there are multiple rumours in the counter and I am not sure which one is true and which one to talk about but this is being predominantly driven by expectations on some kind of announcement coming from the company in the near future. So I would not really like to bet on this at this point otherwise fundamentally and performance wise it is a great company, one can look at it for long term but today’s move has predominantly being based on speculation.

On the Shasun Pharma again you said it is a news driven apart from the news of the capital raise there is also a strong news regarding some vet-medicine tie up with one other large pharma company so that is again a news driven thing. Overall Indian pharma is still missing lot of M&A activity and lot of cooperate activities, corporate action which is probably leading to little bit of uncertainty or little bit of confusion in the mind of the investor but overall it is a great story. Even globally, look at what is happening in Pfizer, AstraZeneca we are seeing the impact of that in India today also.